Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19986356 | 0.81 | ALDH1A1 (0.49) | TDP1LMNARAB9ANPC1MAPT | |
| SCHEMBL1667154 | 0.80 | STAT3 (0.44) | TDP1LMNARAB9ANPC1MAPT | |
| SCHEMBL2427033 | 0.75 | SRC (0.48) | TDP1LMNAALDH1A1STAT3ACHE | |
| SCHEMBL10185057 | 0.75 | ALDH1A1 (0.58) | TDP1LMNARAB9ANPC1L3MBTL1 | |
| SCHEMBL28464077 | 0.73 | MMP8 (0.50) | LMNARAB9ANPC1MAPTNPSR1 | |
| SCHEMBL28468309 | 0.73 | TGM2 (0.42) | TDP1LMNANPSR1ALDH1A1STAT3 | |
| SCHEMBL7132116 | 0.72 | ALDH1A1 (0.41) | TDP1LMNARAB9ANPC1MAPT | |
| SCHEMBL11458883 | 0.71 | BRD4 (0.44) | LMNARAB9ANPC1MAPTPAX8 | |
| SCHEMBL19416738 | 0.69 | RAB9A (0.48) | TDP1LMNARAB9ANPSR1L3MBTL1 | |
| P-Xylene SCHEMBL28141567 | 0.69 | TDP1 (0.61) | TDP1LMNARAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | PHKA1, PHKA2, PHKG1 | TDP1 819/4885LMNA 541/4885RAB9A 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.